Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Abstract

In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).

Keywords

Affiliated Institutions

• Harvard University US
• Johns Hopkins Bayview Medical Center US
• University Hospital Münster DE
• Umeå University SE
• Shih Hsin University TW
• Université Paris-Sud FR
• University College London GB
• University of Messina IT
• Boston Medical Center US
• Hospital Son Llatzer ES
• Samsung Medical Center KR
• Hospital de Santo António PT
• Amyloidosis Foundation US
• Taipei Veterans General Hospital TW
• Centre Hospitalier Universitaire Henri-Mondor FR
• Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán MX
• Hospital Clínic de Barcelona ES
• Konkuk University Medical Center KR
• Inserm FR
• Klinik für Schlafmedizin CH
• Alnylam Pharmaceuticals (United States) US
• National Institute of Emergency Medicine "Pirogov" BG
• Columbia University US
• Istanbul University TR
• Hôpital de la Timone FR
• Vancouver General Hospital CA
• Health Research Institute of the Balearic Islands ES
• Johns Hopkins University US
• Centro Hospitalar do Porto PT
• Mayo Clinic in Arizona US
• Heidelberg University DE
• Sungkyunkwan University KR
• National Taiwan University Hospital TW

Related Publications